Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- OPINION：Just What the Doctor Ordered
April 2, 2007
- St. Gallen Consensus Most Commonly Referred to by Japanese Oncologists in Breast Cancer Treatment: Seminar
April 2, 2007
- Personalized Treatment with Irinotecan Starts
April 2, 2007
- Kissei Aims at 20% Share for Urief in FY2007
April 2, 2007
- Risk of Death Reduced in People Examined for Colorectal Cancer
April 2, 2007
- GSK Enhances Oncology Marketing Forces
April 2, 2007
- Risk of Localized Prostate Cancer Reduced by Soy Products
April 2, 2007
- 152 Generics Approved for the Same Indications as Original Drugs
March 26, 2007
- Generics Should Use the Same Excipients as Original Drugs: Dr Kawashima of Santen
March 26, 2007
- NEW PRODUCT
March 26, 2007
- Kyorin to License at Least 1 Compound Per Year at Late Stage
March 26, 2007
- Korosho Proposes 7 Measures to Promote Innovation
March 26, 2007
- Japan-China Medical Cooperation Initiatives to Symbolize Fraternity: Mr Niwa
March 26, 2007
- R&D NEWS IN BRIEF
March 26, 2007
- FPMAJ to Propose NHI Pricing System Reform Plan in August
March 26, 2007
- Results of J-LIT Subanalysis Published: Banyu
March 26, 2007
- Required Nos. of Japanese Subjects Are Not Exorbitant: Mr Mori from PMDA
March 26, 2007
- Philips Simplicity Event in Hong Kong Highlights Philips' "Sense and Simplicity" in Healthcare
March 26, 2007
- REGULATORY NEWS IN BRIEF
March 26, 2007
- Takeda Acquires Paradigm of the UK
March 26, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…